Ray McDermott

3 ta ish

Azienda Unita' Sanitaria Locale Di Modena

1. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

   Michael J. Overman, Sara Lonardi, Ka Yeung Mark Wong +17

   MaqolaOAOchiq kirish20183 iqtibos

   ABIABI:AkademIndex/2026.other.241935

2. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

   Michael J. Overman, Ray McDermott, Joseph L. Leach +13

   MaqolaOAOchiq kirish20172 iqtibos

   ABIABI:AkademIndex/2026.other.241933

3. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

   Robert J. Motzer, Bernard Escudier, Ray McDermott +24

   Maqola20152 iqtibos

   ABIABI:AkademIndex/2026.other.679071